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HUB-AND-SPOKE	DISPENSING	
MODELS	FOR	COMMUNITY	
PHARMACIESINEUROPE
By: Bernd Rechel
Summary: This article explores experiences in Europe with models of 
“hub-and-spoke” dispensing for community pharmacies. It finds that 
one of the most common forms of this type of model is automated 
“multi-dose dispensing” for older people who take multiple medicines, 
either in nursing homes or at home. Although now firmly established in 
the Nordic countries and the Netherlands, evidence on outcomes and 
costs is limited and does not allow firm conclusions. There is some 
indication that multi-dose dispensing might reduce overall drug use 
and improve treatment adherence, but would increase inappropriate 
drug use and result in fewer changes in drug treatment. Evidence on 
cost implications is missing so far.
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Introduction
The United Kingdom is currently 
considering the introduction of a “hub and 
spoke” dispensing model for community 
pharmacies (see Figure 1). In this model, 
dispensing, which is currently only 
allowed between pharmacies belonging to 
the same retail business, would take place 
across legal entities. Both entities would 
need to be registered pharmacies, but only 
the “spoke” pharmacy would be required 
to have a contract with the National Health 
Service (NHS). The Department of Health 
issued a consultation document with the 
proposed amendments in March 2016. 1  
What is “hub-and-spoke dispensing”?
While the term “hub and spoke 
dispensing” is not widely used outside 
the United Kingdom, it is possible to 
identify relevant experience from other 
European and non-European countries, 
in which prescriptions are collected 
from a “spoke” pharmacy, medication is 
prepared centrally in a “hub” and then 
delivered back to the “spoke” pharmacy 
which dispenses it to the patient. This is 
sometimes called “centralised dispensing” 
and is often related to processes of 
automation (“automated dispensing”) and 
to attempts to prepare centrally various 
medications for the same patient (“multi-
dose dispensing”).
A 2017 publication on the impact 
of automation on the pharmacist 
workforce  2  identified the following 
centralised dispensing models:
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• Automated multi-dose drug dispensing 
for older patients in Australia, 
Denmark, Finland, Norway, Sweden 
and the Netherlands.
• Selective centralised dispensing for 
patients with stable chronic conditions 
in South Africa.
Both of these models follow a “hub-and-
spoke” design but are limited to particular 
groups of patients.
In the first model, these are mainly 
older people, either in nursing homes 
or living at home, who take multiple 
medicines. The medicines are re-packaged 
automatically into unit-dose bags for 
each administration. These single dose 
disposable sachets are labelled with 
patient data, medicine contents and the 
date and time for intake. 3  Repackaging 
is increasingly consolidated at central 
locations and distributed to the consumer 
or the local pharmacy for collection.
‘‘Repackagingisincreasinglyconsolidatedatcentrallocations
In the second model, dispensing takes 
place through a “chronic dispensing 
unit” within the public health sector in 
South Africa. This unit was established to 
maintain medicine supply to people with 
chronic conditions, including HIV/AIDS. 
Once patients are stable, the health facility 
pharmacy sends their prescriptions to the 
central dispensing unit which makes use 
of a semi-automated dispensing process. 
Dispensed medications are sent to the 
health facility for collection by the patient.
Multi-dose dispensing – experience 
in Europe
Within Europe, the use of “hub-and-
spoke” models thus relates in the first 
place to multi-dose dispensing to older 
patients in the Nordic countries and 
the Netherlands. This was confirmed 
by a survey undertaken in 2016 by the 
Pharmaceutical Group of the European 
Union in which it asked its country 
contacts about the existence of inter-
company hub-and-spoke models in other 
EU Member States; 17 responses were 
received. 4  Of those, only four countries 
reported the existence of a “hub-and-
spoke” model: Belgium, Denmark, Finland 
and Germany. However, multi-dose 
dispensing is also being used in Sweden, 
Norway and the Netherlands. Some 
country examples from across Europe 
are given below.
Belgium
In 2012, a Royal Decree was published 
describing the conditions for “individual 
preparation of medication” (IPM) as it is 
called in Belgium. Since then, community 
pharmacies exclusively are allowed to de-
blister solid oral medicines and to dispense 
them in weekly dispensers. In the case 
of automated “individual preparation”, 
the activity may be outsourced to another 
community pharmacy. Several pharmacies 
have developed services for outsourced 
IPM that are often used for the provision 
of medication in homes for older people, 
but rarely in ambulatory care.
Since the providers of automated 
dispensing are always community 
pharmacies, there are no real “hubs”. 
There are about a dozen community 
pharmacies that provide this service 
to homes for older people or to other 
community pharmacies. The provision 
of automated dose dispensing (ADD) to 
homes for older people has been driven 
by economic incentives and the desire to 
achieve a large scale of medications, with 
a decrease in price, but also a decrease 
in quality of care and individual follow-
up of patients. While in theory patients 
are entitled to choose their pharmacy, in 
reality contracts are negotiated between 
providers and institutions for older people. 
Outside of homes for older people, there 
is no real demand for ADD. Some pilot 
projects have been initiated, involving 
home nurses, but these have not been 
rolled out. The service is not covered by 
health insurance benefits, but needs to be 
paid for out-of-pocket.
Germany
Hub-and-spoke models of dispensing, such 
as in multidose dispensing for patients 
receiving multiple medications, are the 
exception rather than the rule in Germany. 
There are generally no pharmacy chains, 
but there are some “hubs” (Blisterzentren) 
which operate industrially, on the basis 
of contracts with pharmacies which order 
medicines for their patients according to 
prescriptions. In general, however, the 
German legal framework, especially the 
rules on reimbursement by the Statutory 
Health Insurance Funds, determines that 
only complete packages in the officially 
authorised sizes shall be dispensed 
to patients. Since 2005, individually 
prepared dispensing (patientenindividuelle 
Verblisterung) can take place if prescribed 
by a doctor explicitly and by special 
exception. It is mainly used in the context 
of the supply of medicines to nursing 
homes, with older patients as the main 
target group, but remains the exception.
Sweden
Already in the 1980s Sweden successively 
replaced manual repackaging of multi-
dose medications from pharmacies with 
automated multi-dose drug dispensing. 
The Swedish medicines agency published 
guidelines on dose dispensing in 2010. 5  
In fact, Sweden has, per capita, the  
largest number of patients receiving multi-
dose dispensing worldwide. 6  In 2009, 
there were 185,000 patients using  
ADD, 5  with between 180,000  7  and 
190,000  8  users in 2011. There are now 
approximately 200,000 patients receiving 
multi-dose dispensing (2018). About 35% 
of them change annually, as many of them 
are older people who die. About 80% of 
users in 2011 were 65 years and older; 
about 40% of users lived in ordinary 
housing, while about 60% lived in nursing 
homes. 7  In 2018 about 50% of recipients of 
multi-dose dispensing were living at home 
and 50% were living in nursing homes.
Finland
In Finland, ADD was launched in 2002 
and implemented through legislation 
in 2011. At the end of 2016, there 
were 49,500 patients using the ADD 
service. 8  In Finland, ADD takes 
predominantly the form of multi-dose 
dispensing (called “dose dispensing” 
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in the Finnish context). The Ministry of 
Social Affairs and Health recommends 
the ADD service for older patients using 
primary health care services either at 
home or in nursing homes to ensure safe 
medication. Most customers (about 95%) 
of dose-dispensing, who are either 
living in nursing homes or at home 
(approximately equally split between the 
two locations), are entitled to publicly 
funded multi-dose dispensing. The 
remaining 5% of customers must request  
to have their medications provided in 
the form of multi-dose dispensing. For 
them, the service is only reimbursed by 
the public insurance system for patients 
aged 75 years and over and using six or 
more reimbursable prescription medicines 
that are suitable for ADD. There are plans 
to change the legislation, so that whoever 
has a physician prescription for multi-dose 
dispensing can be reimbursed.
Netherlands
In the Netherlands, both centralised 
dispensing (such as for repeat 
prescriptions) and multi-dose dispensing 
(for patients taking multiple medications) 
are widely used. 9  ADD robots can be 
located in community pharmacies, but 
more often community pharmacies tend 
to purchase this service from a pharmacy 
that is specialised in ADD. 3  Responsibility 
for clinical and accuracy checks lies 
with the spoke pharmacy, as the hub is 
not a registered pharmacy, but rather a 
supply unit. 10  There were 360,000 ADD 
users in 2011. 8  The largest provider of 
automated customised packaging of 
medications in the Netherlands, including 
multi-dose drug dispensing (MDD), is 
the Pharmacy Voorzorg in Limburg, 
serving approximately 145,000 customers 
through 540 pharmacies. 11 
Limited evidence on outcomes 
and costs
Almost all of the studies on what is termed 
in the United Kingdom “hub-and-spoke 
dispensing” relate to ADD services 
in primary health care in the Nordic 
countries and the Netherlands. ADD has 
been introduced to improve medication 
safety and treatment adherence, 
particularly in older patients with multiple 
medications. Additional anticipated 
benefits are a reduced workload for 
dispensing staff in pharmacies and nurses 
administering the medication, and the 
avoidance of stockpiles of medication 
at home. 3 
While ADD services in primary health 
care are widely promoted and used in the 
Nordic countries and the Netherlands, 
evidence on outcomes is so far very 
limited. 5  A study pointed out in 2014 that 
there was no conclusive evidence with 
regard to patient safety and adherence 
using ADD automated multi-drug use 
dispensing. 7  A systematic review of the 
influence of ADD on the appropriateness 
of medication use, medication safety, and 
costs in primary health care published 
in 2013, 5  only identified seven relevant 
studies. None were randomised controlled 
studies, but four studies used controls. 
The review concluded that evidence 
on appropriateness and safety is so far 
limited, but that overall the few identified 
studies suggested that patients using ADD 
have more inappropriate drugs (see below), 
although ADD may improve medication 
safety in terms of reducing discrepancies 
in medication records between GPs and 
home care services. The review did not 
identify any studies related to costs. 5 
Overall and inappropriate drug use
A nationwide cohort study of all primary 
care patients in Finland aged 65 years 
and older who were enrolled in the ADD 
service in 2007 (n=2073), with a control 
group matched by gender, age, area of 
residence and number of prescription 
drugs reimbursed, found that overall drug 
use was decreased after the initiation 
of the ADD service compared to the 
controls. 8 
However, ADD may introduce new 
types of medication errors. A pragmatic 
randomised controlled study of patients 
using six community pharmacies in 
the Netherlands, with 63 patients in the 
intervention group and 55 patients in the 
waiting-list group, found a high number 
of drug-related problems among patients 
using multi-dose dispensing, as identified 
by a medication review. 12  Several studies 
from Sweden have found that patients 
using ADD are at an increased risk 
of receiving inappropriate medicines 
such as long-acting benzodiazepines, 
anticholinergic medicines, and three 
or more psychotropic medicines and 
that there are fewer changes in their 
Figure 1: Hub-and-spoke dispensing 
Source: Author’s compilation 
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pharmaceutical treatment. 5   13 – 17  This may 
occur because prescriptions are less likely 
to be checked and changed.
‘‘provideservicestoolderpeoplewhotakemultiplemedicines
Treatment adherence
A study examined self-reported 
medication adherence and knowledge of 
older patients (at least 65 years old and 
taking at least five oral drugs) receiving 
their drugs via multi-dose drug dispensing 
(MDD users) with patients receiving 
manually dispensed drugs (non-MDD 
users). The study was based on the random 
selection of 112 MDD users from eight 
community pharmacies in the Netherlands, 
with 96 non-MDD users matched on 
age and gender. 18  The study found that 
older patients receiving their drugs via 
MDD reported a higher self-reported 
medication adherence (81% versus 58%) 
compared with patients receiving 
manually dispensed drugs, despite a lower 
knowledge and lower cognitive function 
among patients receiving MDD. 12   18 
Conclusions
Several countries in Europe have 
embraced models of “hub-and-spoke” 
dispensing that are somewhat similar to 
those anticipated in the United Kingdom. 
These are in particular the Nordic 
countries and the Netherlands. However, 
“hub-and-spoke” dispensing seems to be 
predominantly used to provide services to 
older people who take multiple medicines, 
either at home or, more commonly, in 
nursing homes. It is known as “multi-
dose dispensing” in which medicines are 
re-packaged automatically into unit-dose 
bags for each time of administration. 
Multi-dose dispensing most often 
takes place for clearly defined groups 
of patients, often with a minimum age 
and a minimum number of prescribed 
medications; it tends to be reimbursed by 
the statutory health system.
Although now firmly established in 
these countries, evidence on outcomes 
and costs is limited and does not allow 
for firm conclusions. There is evidence 
from Finland that found that multi-dose 
dispensing might reduce overall drug use, 
but studies in Sweden found an increase 
in inappropriate drug use and fewer 
changes in drug treatment. There is also 
some indication of improved treatment 
adherence, but so far evidence on cost 
implications is missing.
References
 1  Department of Health. Amendments to the 
Human Medicines Regulations 2012: ‘Hub and spoke’ 
dispensing, prices of medicines on dispensing labels, 
labelling requirements and pharmacists’ exemption. 
Consultation document. London: Department of 
Health, 2016.
 2  Spinks J, Jackson J, Kirkpatrick CM, Wheeler 
AJ. Disruptive innovation in community pharmacy – 
Impact of automation on the pharmacist workforce. 
Res Social Adm Pharm. 2017;13(2):394 – 7.
 3  Cheung KC, van den Bemt PM, Bouvy ML, 
Wensing M, De Smet PA. Medication incidents 
related to automated dose dispensing in community 
pharmacies and hospitals – a reporting system study. 
PLoS One. 2014;9(7):e101686.
 4  Pharmaceutical Group of the European Union. 
PGEU Fact Sheet: Hub and spoke. Brussels: 
Pharmaceutical Group of the European Union; 2016.
 5  Sinnemaki J, Sihvo S, Isojarvi J, Blom M, 
Airaksinen M, Mantyla A. Automated dose dispensing 
service for primary healthcare patients: a systematic 
review. Syst Rev. 2013;2:1.
 6  Waller J. Personal communication, 14 February 
2018.
 7  Bardage C, Ekedahl A, Ring L. Health care 
professionals’ perspectives on automated multi-
dose drug dispensing. Pharm Pract (Granada). 
2014;12(4):470.
 8  Sinnemaki J, Airaksinen M, Valaste M, 
Saastamoinen LK. Impact of the automated dose 
dispensing with medication review on geriatric 
primary care patients drug use in Finland: a 
nationwide cohort study with matched controls. 
Scand J Prim Health Care. 2017;35(4):379 – 86.
 9  Moss F. Personal communication, 20 February 
2018.
 10  National Pharmaceutical Association. Background 
paper on automation and Hub and Spoke. London: 
National Pharmaceutical Association, 2016.
 11  Pharmacy Voorzorg. Website Pharmacy Voorzorg. 
Available at: https://www.apotheekvoorzorg.nl
 12  Kwint H-F. Improving appropriate medication use 
for older people in primary care, PhD thesis. Utrecht: 
Utrecht University; 2013.
 13  Johnell K, Fastbom J. Multi-dose drug dispensing 
and inappropriate drug use: A nationwide register-
based study of over 700,000 elderly. Scand J Prim 
Health Care. 2008;26(2):86 – 91.
 14  Sjoberg C, Edward C, Fastbom J, et al. Association 
between multi-dose drug dispensing and quality of 
drug treatment – a register-based study. PLoS One. 
2011;6(10):e26574.
 15  Wallerstedt SM, Fastbom J, Johnell K, Sjoberg C, 
Landahl S, Sundstrom A. Drug treatment in older 
people before and after the transition to a multi-dose 
drug dispensing system – a longitudinal analysis. 
PLoS One. 2013;8(6):e67088.
 16  Sjoberg C, Ohlsson H, Wallerstedt SM. 
Association between multi-dose drug dispensing 
and drug treatment changes. Eur J Clin Pharmacol. 
2012;68(7):1095 – 101.
 17  Belfrage B, Koldestam A, Sjoberg C, 
Wallerstedt SM. Prevalence of suboptimal drug 
treatment in patients with and without multidose 
drug dispensing – a cross-sectional study. Eur J Clin 
Pharmacol. 2014;70(7):867 – 72.
 18  Kwint HF, Stolk G, Faber A, Gussekloo J, 
Bouvy ML. Medication adherence and knowledge 
of older patients with and without multidose drug 
dispensing. Age Ageing. 2013;42(5):620 – 6.
